Fingolimod Reduces Direct Medical Costs Compared to Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis in the Netherlands. Heisen M, Treur M, Van der Hel W, Frequin S, Groot M, Verheggen B J Med Econ. 2012 Jun 28. PMID: 22737996. Abstract CommentRecommendBookmarkWatch